Diphenoxylate/Atropine Oral Suspension (Anhydrous)
Diphenoxylate/Atropine is a compounded formulation containing Diphenoxylate, Atropine, prepared by Mixlab for veterinary use. Available by prescription.
How to Give Anhydrous Oral Suspension
Oral Suspension (Anhydrous) is a liquid medication that does not contain water in its base. This might be an oil-based or other special base to help stabilize the medicine. It will look like a regular liquid medication, but often needs a good shake because the drug can settle. Here's how to give it:
- Shake well each time to mix the medication (5-10 seconds).
- Measure the dose using the syringe/dropper provided or one recommended by your vet. Insert the top of the oral syringe into the bottle adapter. Turn the bottle upside down and pull the plunger until the medicine reaches the volume required
- Hold your pet steady: a towel or helper can assist with squirmy pets.
- Administer the dose slowly into the side of the mouth. Allow small pauses if needed for swallowing.
- Raise the head slightly to help the medication go down and clean any spills with a little water or tissue.
- Praise your pet and offer a treat or water (unless advised against feeding right after).
- Clean the syringe with water immediately after use. Store the bottle as directed, out of sunlight.
- Consistency is key: Shake each time, measure accurately, and contact your vet if any issues arise.
This compounded formulation combines diphenoxylate, an opioid antidiarrheal, with atropine, an anticholinergic — two different drug classes. In compounding practice, clinicians may consider a combination like this for a multi-targeted approach. Your veterinarian determines whether it is appropriate based on your animal's diagnostic findings.
At a pharmacological level, diphenoxylate acts as an opioid agonist that binds to mu-receptors in the gastrointestinal tract. This mechanism manages the segmenting contractions of the intestinal smooth muscle and increases the resistance to luminal flow, providing a method for slowing the movement of intestinal contents. By increasing the time that fluids and nutrients remain in contact with the intestinal mucosa, it provides a method for managing stool consistency and frequency.
Atropine is included in this formulation at a sub-therapeutic dose primarily to discourage intentional overuse, as its anticholinergic properties produce localized effects such as dry mouth if taken in excessive quantities. However, at clinical doses, the atropine component may also provide a minor contribution to managing gastrointestinal secretions. Your veterinarian will determine the clinical appropriateness of this combination based on your pet’s physical examination, hydration status and the suspected cause of the gastrointestinal challenge.
This description reflects the general pharmacology of the active ingredient's drug class; your veterinarian determines whether this approach is appropriate for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
Commonly observed effects following the administration of diphenoxylate and atropine include sedation, lethargy and localized digestive changes such as constipation or a temporary decrease in appetite. Because it is a derivative of the meperidine family, some pets may exhibit behavioral shifts including euphoria or increased sensitivity to sound. Owners should monitor their pet for any observational signs of abdominal discomfort, bloating or significant changes in mental energy and contact their veterinarian promptly with any concerns regarding the patient's response.
This medication is typically used with extra caution or avoided in patients with known liver disease, respiratory compromise, the relevant ophthalmic condition or localized head injuries. It is also carefully evaluated in pets presented with infectious enteritis where the retention of bacterial toxins in the gut could influence the recovery process. Significant interactions can occur if diphenoxylate is administered concurrently with other central nervous system depressants, monoamine oxidase inhibitors (MAOIs) or specific behavioral medications. Your veterinarian is the right person to provide guidance on the necessary duration of use and the proper monitoring schedule to ensure the management approach remains suitable for your pet's digestive health.
Yes. This combination is a prescription medication and a controlled substance that can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all legal and regulatory requirements before preparing any medication.
Yes. While this combination is available in commercial tablet and liquid formats, Mixlab specializes in compounding the active ingredients into customized strengths and flavored dosage forms—such as flavored oral liquids or smaller capsules—to suit the specific weight and needs of your dog. The decision between a commercial and compounded product rests with the prescribing veterinarian.
Atropine is primarily included as a safety feature to manage the risk of improper use of the opioid component. At very high doses, the atropine produces observational signs like dry mouth or blurred vision, though at standard veterinary doses, it typically has minimal systemic influence.
Veterinarians often discuss that observational signs of managed motility are typically seen within a few hours of administration. Your veterinarian will provide guidance on the expected timeline and what progress indicators to monitor during the management course.
Veterinarians typically exercise extra caution when discussing diphenoxylate for feline patients, as some cats may exhibit paradoxical excitement or significant sensitivity to opioids. You should only administer this medication to your cat if it has been specifically authorized and directed by your veterinarian.
